Elliott F. Winton

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · New England Journal of Medicine · 2012 · 2K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · Journal of Hematology & Oncology · 2017 · 427 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis

Ruben A. Mesa, Jean‐Jacques Kiladjian, John Catalano et al. · Journal of Clinical Oncology · 2017 · 367 citations · Full text

Medicine, Hematology, Pharmacology +12

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

Claire Harrison, Nicolaas Schaap, Alessandro M. Vannucchi et al. · The Lancet Haematology · 2017 · 330 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +5

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

Claire Harrison, Alessandro M. Vannucchi, Uwe Platzbecker et al. · The Lancet Haematology · 2017 · 315 citations

Medicine, Hematology, Pharmacology +5